Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on ZLAB stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonathan Chang’s rating is based on several key factors that highlight Zai Lab’s potential for growth and profitability. The company has reaffirmed its full-year revenue guidance and aims to achieve profitability by the end of the year, despite reporting lower-than-expected revenues in the second quarter of 2025. This commitment to financial targets suggests a strong underlying business strategy and operational execution.
Moreover, Zai Lab’s wholly-owned asset, ZL-1310, has shown promising results in treating small cell lung cancer, positioning the company to compete on a global scale beyond its initial focus on the Chinese market. The management’s confidence in an accelerated approval path for ZL-1310, coupled with a robust pipeline of commercial and developmental assets, underpins the Buy rating. The experienced management team further strengthens the company’s prospects, making it an attractive investment opportunity in the biopharmaceutical sector.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $69.00 price target.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZLAB in relation to earlier this year.